P/E ratio for Neuren Pharmaceuticals (NEU.AX)
P/E ratio at the end of 2023: 19.5
According to Neuren Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.918. At the end of 2023 the company had a P/E ratio of 19.5.
P/E ratio history for Neuren Pharmaceuticals from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2023 | 19.5 | -99.62% |
| 2022 | > 1000 | -9881.16% |
| 2021 | -52.3 | 305.04% |
| 2020 | -12.9 | -40.3% |
| 2019 | -21.6 | -147% |
| 2018 | 46.0 | -132.48% |
| 2017 | -142 | 1776.77% |
| 2016 | -7.55 | -41.75% |
| 2015 | -13.0 | -25.57% |
| 2014 | -17.4 | 89.19% |
| 2013 | -9.20 | 78.92% |
| 2012 | -5.14 | 81.44% |
| 2011 | -2.84 | 248.05% |
| 2010 | -0.8146 | -101.24% |
| 2009 | 65.8 | -47387.89% |
| 2008 | -0.1392 | -90.93% |
| 2007 | -1.53 | -58.92% |
| 2006 | -3.74 | -34.95% |
| 2005 | -5.74 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.